SCHEMBL17358798

SCHEMBL17358798

CC(C)(C)N1CCC[C@@H]1c1cccc(F)c1

nearest known ligand 0.66

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
RIPK1 Q13546 2/20 0.61
MAOB P27338 2/20 0.44
MAOA P21397 1/20 0.44
TSHR P16473 1/20 0.43
PDE5A O76074 1/20 0.42
JAK2 O60674 1/20 0.41
NTRK1 P04629 1/20 0.41
LMNA P02545 1/20 0.40
PIK3C3 Q8NEB9 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17358800 1.00 RIPK1 (0.61) RIPK1MAOBMAOATSHRPDE5A
SCHEMBL24775063 0.83 DRD2 (0.46) RIPK1MAOBMAOA
SCHEMBL24775360 0.82 DRD2 (0.48) RIPK1PIK3C3
SCHEMBL24775482 0.82 RIPK1 (0.44) RIPK1MAOBMAOATSHRPDE5A
SCHEMBL22473219 0.80 CHRNB2 (0.59) RIPK1
SCHEMBL13388673 0.80 CHRNB2 (0.59) RIPK1
SCHEMBL22473392 0.80 CHRNB2 (0.59) RIPK1
SCHEMBL21859861 0.80 CHRNB2 (0.64) RIPK1LMNA
SCHEMBL4292933 0.80 CHRNB2 (0.64) RIPK1LMNA
SCHEMBL27112626 0.80 CHRNB2 (0.64) RIPK1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9782391-B2 Substituted imidazo[1,2-a]pyridine compounds as tropomyosin receptor kinase a (TrkA) inhibitors DR. REDDY'S LABORATORIES LTD. (IN) 2017-10-10 US disclosed
US-20160279109-A1 SUBSTITUTED IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS TROPOMYOSIN RECEPTOR KINASE A (TrkA) INHIBITORS DR. REDDY'S LABORATORIES LTD. (IN) 2016-09-29 US disclosed
US-9394305-B2 Substituted imidazo[1,2-a]pyridine compounds as tropomyosin receptor kinase a (TrkA) inhibitors DR. REDDY'S LABORATORIES LTD. (IN) 2016-07-19 US disclosed
US-20150368238-A1 SUBSTITUTED IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS TROPOMYOSIN RECEPTOR KINASE A (TrkA) INHIBITORS DR. REDDY'S LABORATORIES LTD. (IN) 2015-12-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160279109-A1 SUBSTITUTED IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS TROPOMYOSIN RECEPTOR KINASE A (TrkA) INHIBITORS NTRK1, NTRK3, MUSK RIPK1 771/4885MAOB 1103/4885MAOA 576/4885
US-20150368238-A1 SUBSTITUTED IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS TROPOMYOSIN RECEPTOR KINASE A (TrkA) INHIBITORS NTRK1, NTRK3, MUSK RIPK1 771/4885MAOB 1103/4885MAOA 576/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.